Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against Mycobacterium tuberculosis

Francesca Rinaldi, Sara Tengattini, Luciano Piubelli, Roberta Bernardini, Francesca Mangione, Teodora Bavaro, Gregorino Paone, Maurizio Mattei, Loredano Pollegioni, Gaetano Filice, Caterina Temporini, Marco Terreni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tuberculosis is the deadliest infectious disease in the world. The variable efficacy of the current treatments highlights the need for more effective agents against this disease. In the past few years, we focused on the investigation of antigenic glycoconjugates starting from recombinant Ag85B (rAg85B), a potent protein antigen from Mycobacterium tuberculosis. In this paper, structural modifications were rationally designed in order to obtain a rAg85B variant protein able to maintain its immunogenicity after glycosylation. Lysine residues involved in the main T-epitope sequences (namely, K30 and K282) have been substituted with arginine to prevent their glycosylation by a lysine-specific reactive linker. The effectiveness of the mutation strategy and the detailed structure of resulting neo-glycoconjugates have been studied by intact mass spectrometry, followed by peptide and glycopeptide mapping. The effect of K30R and K282R mutations on the T-cell activity of rAg85B has also been investigated with a preliminary immunological evaluation performed by enzyme-linked immunospotting on the different variant proteins and their glycosylation products. After glycosylation, the two variant proteins with an arginine in position 30 completely retain the original T-cell activity, thus representing adequate antigenic carriers for the development of efficient glycoconjugate vaccines against tuberculosis.

Original languageEnglish
Pages (from-to)23171-23180
Number of pages10
JournalRSC Advances
Volume8
Issue number41
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Glycosylation
Glycoconjugates
T-cells
Proteins
Arginine
Lysine
Epitopes
Vaccines
Glycopeptides
Antigens
Peptides
Mass spectrometry
Enzymes

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against Mycobacterium tuberculosis. / Rinaldi, Francesca; Tengattini, Sara; Piubelli, Luciano; Bernardini, Roberta; Mangione, Francesca; Bavaro, Teodora; Paone, Gregorino; Mattei, Maurizio; Pollegioni, Loredano; Filice, Gaetano; Temporini, Caterina; Terreni, Marco.

In: RSC Advances, Vol. 8, No. 41, 01.01.2018, p. 23171-23180.

Research output: Contribution to journalArticle

Rinaldi, F, Tengattini, S, Piubelli, L, Bernardini, R, Mangione, F, Bavaro, T, Paone, G, Mattei, M, Pollegioni, L, Filice, G, Temporini, C & Terreni, M 2018, 'Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against Mycobacterium tuberculosis' RSC Advances, vol. 8, no. 41, pp. 23171-23180. https://doi.org/10.1039/C8RA03535K
Rinaldi, Francesca ; Tengattini, Sara ; Piubelli, Luciano ; Bernardini, Roberta ; Mangione, Francesca ; Bavaro, Teodora ; Paone, Gregorino ; Mattei, Maurizio ; Pollegioni, Loredano ; Filice, Gaetano ; Temporini, Caterina ; Terreni, Marco. / Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against Mycobacterium tuberculosis. In: RSC Advances. 2018 ; Vol. 8, No. 41. pp. 23171-23180.
@article{d8c7d17e23604d7a9b5783f10d1abc77,
title = "Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against Mycobacterium tuberculosis",
abstract = "Tuberculosis is the deadliest infectious disease in the world. The variable efficacy of the current treatments highlights the need for more effective agents against this disease. In the past few years, we focused on the investigation of antigenic glycoconjugates starting from recombinant Ag85B (rAg85B), a potent protein antigen from Mycobacterium tuberculosis. In this paper, structural modifications were rationally designed in order to obtain a rAg85B variant protein able to maintain its immunogenicity after glycosylation. Lysine residues involved in the main T-epitope sequences (namely, K30 and K282) have been substituted with arginine to prevent their glycosylation by a lysine-specific reactive linker. The effectiveness of the mutation strategy and the detailed structure of resulting neo-glycoconjugates have been studied by intact mass spectrometry, followed by peptide and glycopeptide mapping. The effect of K30R and K282R mutations on the T-cell activity of rAg85B has also been investigated with a preliminary immunological evaluation performed by enzyme-linked immunospotting on the different variant proteins and their glycosylation products. After glycosylation, the two variant proteins with an arginine in position 30 completely retain the original T-cell activity, thus representing adequate antigenic carriers for the development of efficient glycoconjugate vaccines against tuberculosis.",
author = "Francesca Rinaldi and Sara Tengattini and Luciano Piubelli and Roberta Bernardini and Francesca Mangione and Teodora Bavaro and Gregorino Paone and Maurizio Mattei and Loredano Pollegioni and Gaetano Filice and Caterina Temporini and Marco Terreni",
year = "2018",
month = "1",
day = "1",
doi = "10.1039/C8RA03535K",
language = "English",
volume = "8",
pages = "23171--23180",
journal = "RSC Advances",
issn = "2046-2069",
publisher = "Royal Society of Chemistry",
number = "41",

}

TY - JOUR

T1 - Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against Mycobacterium tuberculosis

AU - Rinaldi, Francesca

AU - Tengattini, Sara

AU - Piubelli, Luciano

AU - Bernardini, Roberta

AU - Mangione, Francesca

AU - Bavaro, Teodora

AU - Paone, Gregorino

AU - Mattei, Maurizio

AU - Pollegioni, Loredano

AU - Filice, Gaetano

AU - Temporini, Caterina

AU - Terreni, Marco

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tuberculosis is the deadliest infectious disease in the world. The variable efficacy of the current treatments highlights the need for more effective agents against this disease. In the past few years, we focused on the investigation of antigenic glycoconjugates starting from recombinant Ag85B (rAg85B), a potent protein antigen from Mycobacterium tuberculosis. In this paper, structural modifications were rationally designed in order to obtain a rAg85B variant protein able to maintain its immunogenicity after glycosylation. Lysine residues involved in the main T-epitope sequences (namely, K30 and K282) have been substituted with arginine to prevent their glycosylation by a lysine-specific reactive linker. The effectiveness of the mutation strategy and the detailed structure of resulting neo-glycoconjugates have been studied by intact mass spectrometry, followed by peptide and glycopeptide mapping. The effect of K30R and K282R mutations on the T-cell activity of rAg85B has also been investigated with a preliminary immunological evaluation performed by enzyme-linked immunospotting on the different variant proteins and their glycosylation products. After glycosylation, the two variant proteins with an arginine in position 30 completely retain the original T-cell activity, thus representing adequate antigenic carriers for the development of efficient glycoconjugate vaccines against tuberculosis.

AB - Tuberculosis is the deadliest infectious disease in the world. The variable efficacy of the current treatments highlights the need for more effective agents against this disease. In the past few years, we focused on the investigation of antigenic glycoconjugates starting from recombinant Ag85B (rAg85B), a potent protein antigen from Mycobacterium tuberculosis. In this paper, structural modifications were rationally designed in order to obtain a rAg85B variant protein able to maintain its immunogenicity after glycosylation. Lysine residues involved in the main T-epitope sequences (namely, K30 and K282) have been substituted with arginine to prevent their glycosylation by a lysine-specific reactive linker. The effectiveness of the mutation strategy and the detailed structure of resulting neo-glycoconjugates have been studied by intact mass spectrometry, followed by peptide and glycopeptide mapping. The effect of K30R and K282R mutations on the T-cell activity of rAg85B has also been investigated with a preliminary immunological evaluation performed by enzyme-linked immunospotting on the different variant proteins and their glycosylation products. After glycosylation, the two variant proteins with an arginine in position 30 completely retain the original T-cell activity, thus representing adequate antigenic carriers for the development of efficient glycoconjugate vaccines against tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=85049361702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049361702&partnerID=8YFLogxK

U2 - 10.1039/C8RA03535K

DO - 10.1039/C8RA03535K

M3 - Article

VL - 8

SP - 23171

EP - 23180

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 41

ER -